| Somaiah, Neeta |
NCT02815995: Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes |
|
|
| Completed | 2 | 56 | US | Durvalumab, Tremelimumab | M.D. Anderson Cancer Center, MedImmune LLC | Advanced and/or Metastatic Sarcoma | 06/24 | 06/24 | | |
NCT06087263: Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting. |
|
|
| Recruiting | 2 | 30 | US | Regorafenib, Stivarga® | M.D. Anderson Cancer Center, Bayer | Gastrointestinal Stromal Tumors | 07/32 | 07/34 | | |
Keynote MK-3475-B66, NCT03611868: A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 230 | US, RoW | Phase 1b: APG-115+pembrolizumab, KEYTRUDA® | Ascentage Pharma Group Inc., Merck Sharp & Dohme LLC | Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors (MPNST) | 12/24 | 03/25 | | |
NCT04936178: A Study of NB003 in Patients With Advanced Malignancies |
|
|
| Recruiting | 1 | 258 | Europe, US, RoW | NB003 tablets | Ningbo Newbay Technology Development Co., Ltd | Advanced Solid Tumor | 07/25 | 12/25 | | |
StrateGIST 1, NCT05489237: First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors |
|
|
| Recruiting | 1 | 269 | Europe, US, RoW | IDRX-42 | IDRx, Inc. | Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer | 04/26 | 09/26 | | |
| Zhu, Xiaofan |
TAK-620-2004, NCT05319353 / 2021-004279-15: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT) |
|
|
| Active, not recruiting | 3 | 80 | Europe, Japan, US, RoW | Maribavir, TAK-620 | Takeda, Takeda Development Center Americas, Inc. | Cytomegalovirus (CMV) | 01/27 | 01/27 | | |
NCT05334823: A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents |
|
|
| Recruiting | 2 | 100 | RoW | pCAR-19B cells | Chongqing Precision Biotech Co., Ltd | Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia | 12/24 | 07/25 | | |
NCT06179524: CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL |
|
|
| Recruiting | 2 | 100 | RoW | CAR-T-19 cell injection | Beijing Yongtai Ruike Biotechnology Company Ltd | Relapsed B-cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic Leukemia | 06/25 | 04/27 | | |
NCT05667506: A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) |
|
|
| Recruiting | 1/2 | 47 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | B-cell Acute Lymphoblastic Leukemia | 07/25 | 12/26 | | |
NCT04501614 / 2019-002549-39: A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia |
|
|
| Terminated | 1/2 | 11 | Europe, US, RoW | Ponatinib, Chemotherapy Agents | Takeda, Takeda Development Center Americas, Inc. | Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL) | 12/23 | 07/24 | | |
NCT05727683: CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 1 | 33 | RoW | CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, Fludarabine, Cyclophosphamide | Shanghai Ming Ju Biotechnology Co., Ltd. | Acute Lymphocytic Leukemia | 10/23 | 07/25 | | |
| Zhang, Luo |
NCT05038202: Study of Bencycloquidium Bromide Nasal Spray in the Treatment of Moderate-severe Persistent Allergic Rhinitis |
|
|
| Active, not recruiting | 4 | 450 | RoW | Bencycloquidium Bromide Nasal Spray, BILITING, Mometasone Furoate Aqueous Nasal Spray, NASONEX | Yingu Pharmaceutical Co., Ltd | Allergic Rhinitis | 04/24 | 06/24 | | |
NCT05908032: Study of CM310 in Subjects With Allergic Rhinitis |
|
|
| Completed | 3 | 108 | RoW | CM310, Placebo | Keymed Biosciences Co.Ltd | Allergic Rhinitis | 12/23 | 12/23 | | |
NCT06516302: A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps |
|
|
| Not yet recruiting | 3 | 228 | NA | GR1802, Placebo | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Chronic Rhinosinusitis With Nasal Polyps | 01/26 | 10/26 | | |
| Active, not recruiting | 3 | 296 | Europe, Japan, US, RoW | Benralizumab 30 mg, Matched placebo | AstraZeneca | Nasal Polyposis | 08/24 | 10/25 | | |
|
NCT05436275: A Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （CROWNS-2） |
|
|
| Completed | 3 | 180 | RoW | CM310, Placebo | Keymed Biosciences Co.Ltd | Chronic Rhinosinusitis With Nasal Polyposis | 06/24 | 06/24 | | |
NCT06639295: A Study to Evaluate 611 in Patients with Chronic Rhinosinusitis with Nasal Polyps |
|
|
| Not yet recruiting | 3 | 240 | RoW | 611, Placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Sinusitis, Nasal Polyps | 12/25 | 08/26 | | |
NCT05131464: The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps |
|
|
| Completed | 2 | 46 | RoW | CM310 | Keymed Biosciences Co.Ltd | Chronic Rhinosinusitis With Nasal Polyps | 01/24 | 01/24 | | |
NCT06171074: Study of CM310 in Subjects With Seasonal Allergic Rhinitis |
|
|
| Not yet recruiting | 2 | 100 | RoW | CM310 | Keymed Biosciences Co.Ltd | Seasonal Allergic Rhinitis | 03/25 | 03/25 | | |
NCT05865496: A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps |
|
|
| Active, not recruiting | 2 | 90 | RoW | 611, Placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Sinusitis, Nasal Polyps, Polyps | 05/24 | 07/24 | | |
NCT06372678: Study of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis |
|
|
| Not yet recruiting | 2 | 90 | RoW | CM326, Placebo | Keymed Biosciences Co.Ltd | Chronic Rhinosinusitis With Nasal Polyps | 06/26 | 06/26 | | |
NCT06439381: Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps |
|
|
| Recruiting | 2 | 120 | RoW | 300mg/600mg of TQH2722 injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Rhinosinusitis | 10/25 | 11/25 | | |
| Recruiting | 2 | 120 | RoW | Stapokibart Injection, Placebo | Keymed Biosciences Co.Ltd | Allergic Rhinitis | 10/25 | 10/25 | | |
NCT05908721: Study of CM310 in Patients With Allergic Rhinitis |
|
|
| Completed | 2 | 100 | RoW | CM310 | Keymed Biosciences Co.Ltd | Allergic Rhinitis | 12/23 | 12/23 | | |
NCT06089278: A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps. |
|
|
| Recruiting | 2 | 160 | RoW | 300mg of TQH2722 injection, 600mg of TQH2722 injection, TQH2722 injection matching placebo | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Sinusitis | 05/25 | 05/25 | | |
NCT05324137: A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps |
|
|
| Completed | 1/2 | 88 | RoW | CM326, Placebo | Keymed Biosciences Co.Ltd | Chronic Rhinosinusitis With Nasal Polyps | 03/24 | 03/24 | | |
| Eugster, Erica |
NCT05493709: Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects with Central Precocious Puberty |
|
|
| Recruiting | 3 | 93 | US, RoW | Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide | Foresee Pharmaceuticals Co., Ltd., QPS Holdings LLC, Changchun GeneScience Pharmaceutical Co., Ltd. | Puberty; Precocious, Central | 11/25 | 06/26 | | |
| Hu, Wei |
NCT03388593: Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure. |
|
|
| Recruiting | 3 | 1600 | RoW | rhNRG-1, Neucardin™, Placebo | Zensun Sci. & Tech. Co., Ltd. | Chronic Heart Failure | 02/26 | 02/26 | | |
NCT04973735: A Phase I Study of LY-CovMab Injection in Chinese Healthy Subjects |
|
|
| Active, not recruiting | 1 | 42 | RoW | LY-CovMab | Luye Pharma Group Ltd., Shandong Boan Biotechnology Co Ltd | Covid19 | 05/21 | 07/21 | | |
NCT05166837: The Safety of STSA-1002 Following Intravenous Infusion in Healthy Subjects |
|
|
| Completed | 1 | 52 | RoW | STSA-1002 injection, Placebo | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Healthy | 01/23 | 01/23 | | |
NCT05865574: A Comparative Pharmacokinetic Study to Evaluate Different Manufacturing Batches of BAT1706 Injection |
|
|
| Not yet recruiting | 1 | 38 | RoW | BAT1706 Injection, BAT1706 | Bio-Thera Solutions | Healthy Men | 09/23 | 01/24 | | |
NCT05968508: A Randomized, Double-blind, Single-dose, Two-arm Parallel Study to Compare the Pharmacokinetics and Safety of BAT1806 Prefilled Subcutaneous Injection With RoActemra® in Healthy Chinese Male Subjects |
|
|
| Active, not recruiting | 1 | 300 | RoW | BAT1806 prefilled subcutaneous injection/RoActemra® (from EU) | Bio-Thera Solutions | Healthy Men | 12/24 | 04/25 | | |
NCT06182384: A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices |
|
|
| Completed | 1 | 46 | RoW | SHR-1314 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Moderate-to-Severe Plaque Psoriasis | 05/24 | 05/24 | | |
NCT06196580: PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval |
|
|
| Completed | 1 | 24 | RoW | repaglinide; midazolam; SHR4640, repaglinide; midazolam; SHR4640; SHR4640 placebo, repaglinide; midazolam; SHR4640 placebo | Jiangsu HengRui Medicine Co., Ltd. | Gout and Hyperuricemia | 02/24 | 02/24 | | |
| Recruiting | 1 | 84 | RoW | HS-10501 tablet, Placebo | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Healthy Subjects | 01/25 | 06/25 | | |
| Completed | 1 | 65 | RoW | HDM1005 injection or placebo | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Obesity and Overweight | 08/24 | 09/24 | | |
NCT06346925: Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects. |
|
|
| Not yet recruiting | 1 | 18 | RoW | Herombopag Olamine Tablets | Jiangsu HengRui Medicine Co., Ltd. | Adult Patients With Chronic Primary ITP, Adult Patients With SAA Who do Not Respond Well to Immunosuppressive Therapy | 07/24 | 07/24 | | |
NCT06171048: Study Evaluating the Pharmacokinetics of CM310 in Healthy Subjects |
|
|
| Not yet recruiting | 1 | 236 | RoW | CM310 | Keymed Biosciences Co.Ltd | Healthy | 04/25 | 04/25 | | |
NCT06375031: Comparison of HR011408 and NovoRapid® in Subjects With Diabetics |
|
|
| Recruiting | 1 | 30 | RoW | HR011408 injection; HR011408 injection Placebo, NovoRapid®; HR011408 injection Placebo, HR011408 injection Placebo; HR011408 injection | Jiangsu HengRui Medicine Co., Ltd. | Diabetes | 07/24 | 07/24 | | |
NCT06422039: Bioavailability and Food Effects of HRS-7535 Tablets With Different Formulating Processes in Healthy Subjects |
|
|
| Not yet recruiting | 1 | 18 | RoW | HRS-7535（D）Tablets, HRS-7535（C）Tablets | Shandong Suncadia Medicine Co., Ltd. | Type 2 Diabetes Mellitus | 06/24 | 06/24 | | |
NCT06435676: A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects |
|
|
| Recruiting | 1 | 92 | RoW | HRS9531, Placebo | Fujian Shengdi Pharmaceutical Co., Ltd. | Overweight or Obesity; Type 2 Diabetes | 09/24 | 09/24 | | |
| Recruiting | 1 | 50 | RoW | HDM1005 injection or placebo, HDM1005 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Overweight and Obesity | 01/25 | 01/25 | | |
HDG1901-103, NCT06634927: Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects. |
|
|
| Recruiting | 1 | 68 | RoW | Ozempic®, HDG1901 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Type 2 Diabetes | 11/24 | 02/25 | | |
NCT06654960: Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy Subjects |
|
|
| Completed | 1 | 20 | RoW | HRS9531 injection, Metformin Hydrochloride tablets | Fujian Shengdi Pharmaceutical Co., Ltd. | Type 2 Diabetes | 12/24 | 12/24 | | |
NCT06723691: Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects |
|
|
| Active, not recruiting | 1 | 57 | RoW | Acetaminophen, Metformin, Warfarin, Atorvastatin, Digoxin, HRS9531 | Fujian Shengdi Pharmaceutical Co., Ltd. | Type 2 Diabetes | 05/25 | 05/25 | | |
NCT05119647: A Single-Arm Objective Performance Criteria Trial for Intracranial Thrombus Aspiration Catheter |
|
|
| Completed | N/A | 124 | RoW | Thrombus Aspiration Catheter(Ton-bridgeMT) | Zhuhai Tonbridge Medical Tech. Co., Ltd. | Acute Ischemic Stroke | 08/22 | 11/22 | | |
| Li, Jun |
| Active, not recruiting | 4 | 640 | RoW | Tenofovir Amibufenamide（TMF）, HS-10234 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Hepatitis B, Chronic | 06/24 | 09/29 | | |
NCT05115942: Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial. |
|
|
| Completed | 3 | 248 | RoW | Hydronidone capsules, F351, The placebo capsules, N | Beijing Continent Pharmaceutical Co, Ltd. | Liver Fibrosis | 10/24 | 10/24 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) |
|
|
| Active, not recruiting | 3 | 900 | Europe, Canada, Japan, US, RoW | Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib | Eli Lilly and Company | Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6 | 02/24 | 10/27 | | |
NCT05905172: Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis |
|
|
| Recruiting | 3 | 248 | RoW | Hydronidone capsules, F351, The placebo capsules, N | Beijing Continent Pharmaceutical Co, Ltd. | Liver Fibrosis | 06/28 | 10/28 | | |
NCT05395416: Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C |
|
|
| Recruiting | 2/3 | 520 | RoW | HEC74647PA+HEC110114, Antaitavir Hasophate+Yiqibuvir, Placebo | Sunshine Lake Pharma Co., Ltd. | Chronic HCV Infection | 04/23 | 04/23 | | |
NCT04983043: Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure |
|
|
| Completed | 2 | 228 | RoW | Low dose QiShen YiQi Dripping Pills 3 bags, Low dose group, High dose QiShen YiQi Dripping Pills 3 bags, High dose group, QiShen YiQi Dripping Pills placebo 3 bags, Placebo group | Tasly Pharmaceutical Group Co., Ltd | Chronic Heart Failure With Reduced Ejection Fraction | 11/24 | 11/24 | | |
| Active, not recruiting | 1/2 | 121 | RoW | CAR-BCMA T Cells | CARsgen Therapeutics Co., Ltd., Beijing Chao Yang Hospital, The First Affiliated Hospital of Soochow University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University General Hospital, First Affiliated Hospital of Zhejiang University, Beijing Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Xiangya Hospital of Central South University, Peking University People's Hospital, Qilu Hospital of Shandong University, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University | Multiple Myeloma | 12/24 | 12/25 | | |
NCT04384393: Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies |
|
|
| Recruiting | 1 | 30 | RoW | ThisCART19 cells | Fundamenta Therapeutics, Ltd., Anhui Provincial Hospital | B Cell Malignancy | 11/22 | 10/23 | | |
NCT05127135: Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies |
|
|
| Recruiting | 1 | 30 | RoW | ThisCART7 cells | Fundamenta Therapeutics, Ltd., The First Affiliated Hospital of University of Science and Technology of China | T-Acute Lymphoblastic Leukemia, T-cell Non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Lymphoma | 01/23 | 12/23 | | |
NCT05098197: Study on TIL for the Treatment of Advanced Hepatobiliary-Pancreatic Cancers |
|
|
| Recruiting | 1 | 50 | RoW | Tumor Infiltrating Lymphocyte | Shanghai Juncell Therapeutics, Shanghai 10th People's Hospital | Advanced Liver Cancers, Tumor Infiltrating Lymphocyte, Treatment Side Effects, Effects of Immunotherapy, Advanced Pancreatic Cancers | 09/26 | 09/26 | | |
| Completed | N/A | 40 | US | Digital Subtraction Angiography | University Hospitals Cleveland Medical Center, Abbott Medical Devices | Peripheral Artery Disease, Critical Limb Ischemia | 06/24 | 06/24 | | |
| Completed | N/A | 692 | Europe, US | Catheter-Directed Thrombolysis, FlowTriever System | Inari Medical | Pulmonary Embolism, Pulmonary Thrombo-embolism | 03/24 | 04/24 | | |
Promote, NCT05797714: The Effectiveness and Safety of TMF in the Treatment of Chronic Hepatitis B Patients With Normal ALT. |
|
|
| Active, not recruiting | N/A | 200 | RoW | Tenofovir Amibufenamide（TMF）, HengMu | Ruijin Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd. | HBV Infection, Chronic Hepatitis b | 06/24 | 04/26 | | |
ASCENT, NCT06246045: Artificial Intelligence to StrategiCally Enhance Pulmonary Embolism Response Team Activation |
|
|
| Not yet recruiting | N/A | 390 | US | Walking test | University Hospitals Cleveland Medical Center, Inari Medical | Pulmonary Embolism Subacute Massive | 01/26 | 01/26 | | |
NCT05907564: Aventus Thrombectomy System Pulmonary Embolism Clinical Study |
|
|
| Recruiting | N/A | 120 | US | Thrombectomy | Inquis Medical, Inc. | Pulmonary Embolism, Embolism, Embolism and Thrombosis, Vascular Diseases, Cardiovascular Diseases, Lung Diseases, Respiratory Tract Diseases | 03/25 | 03/25 | | |
| Recruiting | N/A | 5000 | Europe, Canada, US, RoW | Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device. | Boston Scientific Corporation | Peripheral Vascular Diseases | 01/28 | 01/28 | | |
C-DIAMOND, NCT04952207: Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C |
|
|
| Recruiting | N/A | 300 | RoW | Direct-acting antiviral agents, daclatasvir, asunaprevir, ombitasvir, paritaprevir, dasabuvir, sofosbuvir, velpatasvir, ledipasvir, elbasvir, grazoprevir, danoprevir, glecaprevir, pibrentasvir, voxilaprevir | Qing XIe, Gilead Sciences, Tigermed Consulting Co., Ltd | Hepatitis C, Chronic | 07/21 | 08/21 | | |
| Wei, Hu |
NCT06361355: Study of CMAB807 Post-change in Manufacturing Site and Prolia in Healthy Volunteers |
|
|
| Completed | 1 | 128 | RoW | Post-change CMAB807, Prolia | Taizhou Mabtech Pharmaceutical Co.,Ltd | Healthy Volunteers | 06/24 | 07/24 | | |
NCT06159101: A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects |
|
|
| Recruiting | 1 | 304 | RoW | HLX13, CN-sourced ipilimumab, EU-sourced ipilimumab group, US-sourced ipilimumab group | Shanghai Henlius Biotech | Healthy Male Volunteers | 05/24 | 05/24 | | |
NCT05734482: Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers |
|
|
| Completed | 1 | 130 | RoW | Secukinumab | Taizhou Mabtech Pharmaceutical Co.,Ltd | Psoriasis | 07/23 | 07/23 | | |
NCT05808673: Study of CMAB807X Pre- and Post-change in Manufacturing Site and Xgeva® in Healthy Volunteers |
|
|
| Withdrawn | 1 | 252 | RoW | Post-change CMAB807X, Pre-change CMAB807X, Xgeva® | Taizhou Mabtech Pharmaceutical Co.,Ltd | Healthy Volunteers | 06/24 | 07/24 | | |
| Li, Ting |
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease |
|
|
| Recruiting | 3 | 440 | Europe, Japan, US, RoW | Belimumab, BENLYSTA, GSK1550188, Placebo | GlaxoSmithKline | Lung Diseases, Interstitial | 10/28 | 12/28 | | |
NCT06716606: A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease |
|
|
| Recruiting | 3 | 225 | RoW | Belimumab | GlaxoSmithKline, ICON plc | Bronchial Diseases | 07/28 | 01/30 | | |
| Recruiting | 2/3 | 240 | Europe, Canada, Japan, US, RoW | EFG PH20 SC, PBO | argenx, argenx BV | Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome | 12/26 | 02/27 | | |
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease |
|
|
| Recruiting | 2/3 | 300 | Europe, Japan, US, RoW | Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo | GlaxoSmithKline | Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic | 07/27 | 07/27 | | |
|
NCT06711991: A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease |
|
|
| Not yet recruiting | 1 | 48 | RoW | TQC3927 powder for inhalation, TQC3927 powder for inhalation placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Obstructive Pulmonary Disease | 12/25 | 01/26 | | |
| Gao, Jing |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
| Jiang, Hui |
NCT05188989: Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction. |
|
|
| Completed | 3 | 765 | RoW | TPN171H 2.5mg group, Simmerafil, TPN171H 5mg group, TPN171H 10mg group, Placebo group | Vigonvita Life Sciences | Erectile Dysfunction | 02/23 | 02/23 | | |
NCT06301854: Long-term Safety of TPN171H Tablet in Erectile Dysfunction. |
|
|
| Recruiting | 3 | 472 | RoW | TPN171H, Simmerafil | Vigonvita Life Sciences | Erectile Dysfunction | 04/25 | 04/25 | | |
NCT05388825: Pharmacodynamic Study of TPN171H Tablets in Patients With Mild to Moderate Erectile Dysfunction |
|
|
| Completed | 2 | 84 | RoW | TPN171H 2.5mg, TPN171H 5mg, TPN171H 10mg, Placebo 5mg, Placebo 10mg | Vigonvita Life Sciences | Erectile Dysfunction | 01/23 | 02/23 | | |
NCT04501614 / 2019-002549-39: A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia |
|
|
| Terminated | 1/2 | 11 | Europe, US, RoW | Ponatinib, Chemotherapy Agents | Takeda, Takeda Development Center Americas, Inc. | Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL) | 12/23 | 07/24 | | |
| Completed | 1 | 18 | RoW | TPN171H 10mg, TPN171H Placebo | Vigonvita Life Sciences | Erectile Dysfunction | 12/22 | 12/22 | | |
| yang, jianwei |
| Active, not recruiting | 3 | 408 | RoW | KN046, placebo | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Pancreatic Ductal Adenocarcinoma | 04/24 | 08/24 | | |
G-HOPE-001, NCT06238843: A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Enrolling by invitation | 3 | 450 | RoW | irinotecan, IBI343, paclitaxel | Innovent Biologics (Suzhou) Co. Ltd. | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | 12/26 | 12/27 | | |
NCT05019794: Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations |
|
|
| Recruiting | 2a | 80 | RoW | Infigratinib, BGJ398 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor | 12/22 | 12/23 | | |
|
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
SPH5030-201, NCT06434597: A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. |
|
|
| Recruiting | 2 | 60 | RoW | SPH5030 | Shanghai Pharmaceuticals Holding Co., Ltd | Biliary Tract or Colorectal Cancer With Her2-positive/Mutated | 12/26 | 12/26 | | |
NCT05879055: A Study of PM8002 in Combination With Chemotherapy in Patients With NEN |
|
|
| Recruiting | 2 | 60 | RoW | PM8002, FOLFIRI | Biotheus Inc. | Neuroendocrine Neoplasm | 01/27 | 01/28 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 |
|
|
| Recruiting | 1 | 162 | RoW | CMG901 | Keymed Biosciences Co.Ltd | Advanced Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer | 05/24 | 10/24 | | |
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
| Recruiting | 1 | 556 | RoW | IBI363 + chemotherapy, IBI363 + Investigator's Choice SOC | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Malignancies | 06/25 | 12/26 | | |
NCT05946226: A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors |
|
|
| Recruiting | 1 | 18 | RoW | IMC002 injection, Autologous Claudin 18.2 specific CAR-T cell injection | Suzhou Immunofoco Biotechnology Co., Ltd | Advanced Digestive System Tumor | 12/25 | 12/25 | | |
| Zhang, Jing |
NCT05536726: A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis |
|
|
| Recruiting | 3 | 450 | RoW | 608 Q2W, 608 Q4W, Placebo, PBO | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Psoriasis | 07/23 | 06/24 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
ReNEW, NCT06373731: Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD) |
|
|
| Recruiting | 3 | 360 | Europe, US, RoW | Elamipretide, Elamipretide HCL, Placebo | Stealth BioTherapeutics Inc. | Age Related Macular Degeneration (ARMD) | 08/26 | 08/27 | | |
| Recruiting | 3 | 360 | RoW | ZX-7101A, Placebo | Nanjing Zenshine Pharmaceuticals | Respiratory Viral Infection | 01/25 | 03/25 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
NCT06569524: Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH) |
|
|
| Recruiting | 2 | 120 | RoW | TQA2225/AP025 or TQA2225/AP025 Placebo 25mg, TQA2225/AP025 or TQA2225/AP025 Placebo 50mg | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Non-alcoholic Steatohepatitis | 12/26 | 12/27 | | |
| Recruiting | 2 | 140 | US | ALK-001, C20-D3-Retinyl Acetate, C20 Deuterated vitamin A, Placebo | Alkeus Pharmaceuticals, Inc. | Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related) | 12/24 | 03/25 | | |
NCT05328531: Clinical Study of Genakumab for Injection in Patients With Acute Gout |
|
|
| Active, not recruiting | 1/2 | 121 | RoW | Genakumab for Injection, Placebo for Genakumab for Injection | GeneScience Pharmaceuticals Co., Ltd., Huashan Hospital, Hainan General Hospital, Linyi People's Hospital, The Second Affiliated Hospital of Chongqing Medical University, Changhai Hospital, The First Affiliated Hospital with Nanjing Medical University, Shengjing Hospital, Affiliated Hospital of Nantong University | Acute Gout | 05/22 | 05/22 | | |
NCT06302374: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults |
|
|
| Completed | 1/2 | 202 | RoW | GR2001, Placebo, HTIG, Tetanus Toxoid | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Tetanus | 11/23 | 02/24 | | |
